Coherus Oncology, Inc. (CHRS)

Market Cap	245.26M +167.7%
Revenue (ttm)	46.88M +48.0%
Net Income	186.27M
EPS	1.52
Shares Out	154.25M
PE Ratio	1.32
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,532,142
Open	1.650
Previous Close	1.650
Day's Range	1.580 - 1.675
52-Week Range	0.710 - 2.616
Beta	1.02
Analysts	Strong Buy
Price Target	7.80 (+390.57%)
Earnings Date	May 11, 2026

About CHRS

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS
• Website: https://www.coherus.com

Financial Performance

In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.

Analyst Summary

According to 7 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price target is $7.8, which is an increase of 390.57% from the latest price.

Price Target

$7.8

(390.57% upside)

Analyst Consensus: Strong Buy